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ABSTRACT
RNAmethyltransferases (MTases) catalyse the transfer of a methyl group to their RNA substrates usingmost-
often S-adenosyl-L-methionine (SAM) as cofactor. Only few RNA-bound MTases structures are currently
available due to the difficulties in crystallising RNA:protein complexes. The lack of complex structures results
in poorly understood RNA recognition patterns and methylation reaction mechanisms. On the contrary,
many cofactor-bound MTase structures are available, resulting in well-understood protein:cofactor recogni-
tion, that can guide the design of bisubstrate analogues thatmimic the state at which both the substrate and
the cofactor is bound. Such bisubstrate analogues were recently synthesized for proteins monomethylating
the N6-atom of adenine (m6A). These proteins include, amongst others, RlmJ in E. coli and METLL3:METT14
andMETTL16 in human. As a proof-of-concept, we here test the ability of the bisubstrate analogues tomimic
the substrate:cofactor bound state during catalysis by studying their binding to RlmJ using differential
scanning fluorimetry, isothermal titration calorimetry and X-ray crystallography. We find that the methylated
adenine base binds in the correct pocket, and thus these analogues could potentially be used broadly to
study the RNA recognition and catalytic mechanism of m6A MTases. Two bisubstrate analogues bind RlmJ
with micro-molar affinity, and could serve as starting scaffolds for inhibitor design against m6A RNA MTases.
The same analogues cause changes in the melting temperature of the m1A RNA MTase, TrmK, indicating
non-selective protein:compound complex formation. Thus, optimization of these molecular scaffolds
for m6A RNA MTase inhibition should aim to increase selectivity, as well as affinity.
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Introduction
The family of S-adenosyl methionine (SAM) dependent
methyltransferases (MTases) comprises protein-, RNA- and
DNA MTases. These proteins transfer methyl groups to differ-
ent positions in protein side-chains, RNAs or DNAs, respec-
tively. One subfamily of RNA MTases covers m6A RNA
MTases that monomethylate the exocyclic N6-atom of adenine
(m6A). This modification is found in all organisms from bac-
teria to human, and in both mRNA, tRNA, rRNA, small
nucleolar RNA, non-coding RNA, and DNA [1,2]. m6A is
involved in stabilizing RNA:RNA interactions as well as indu-
cing RNA:protein interactions (recently reviewed in [3,4]).
A number of m6A RNA MTases have been structurally char-
acterized as either full-length protein, e.g. Ribosomal RNA large
subunit methyltransferase J (RlmJ) that methylates the 23S
rRNA at position A2030 in E. coli [5,6], or as just the catalytic
MTase domain as in e.g. eukaryotic methyltransferase like 16
protein (METTL16) that methylates pre-mRNAs, lncRNAs, and
other ncRNAs [7–9], or METTL3 and METTL14 from the
ternary complex of METTL3:METTL14 and the Wilms tumor
1 associating protein (WTAP) that introduces m6A into mRNAs
[10–12]. Of the known m6A RNA MTases, only METTL16 has
been crystallised in complex with substrate RNA [13]. m6A RNA
MTases are functionally and structurally related to m6A DNA
MTases such as T4Dam or M.TaqI, both of which are structu-
rally characterized in complex with substrate DNA (PDB: 1YFL,
1G38) [14,15].
In the absence of a structure of E. coli RlmJ in complex
with substrate RNA, biochemical studies were performed to
investigate substrate binding. These studies showed that RlmJ
can methylate A2030 in a hairpin fragment of 23S rRNA as
short as 25 bases, with the same efficiency as for full-length
substrate [6]. The m6A2030 modification was suggested to
enhance long-range stacking interactions within the rRNA,
to increase the overall rRNA stability [2]. RlmJ methylates
deproteinized 23S rRNA, indicating that the m6A2030 mod-
ification occurs early in the ribosome biogenesis [5]. The
protein is none-essential, but has been associated with the
ability of bacteria to use DNA as a nutrient [16], and with
repression of plasmid uptake [17].
RNA MTases, as well as protein- and DNA MTases, have
been linked to various types of cancer (reviewed in [18]) or
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rare mitochondrial respiratory chain complex deficiencies
[19,20]. Of these, only protein- and DNA MTases have so
far been targets for drug development. These drugs are
either non-nucleosides or explore the scaffold of the
methyl-donor cofactor SAM as a starting point for inhibitor
design. SAM-derivate inhibitors include e.g. azacytidine
(Vidaza, Celgene), decitabine (Dacogen, SuperGen),
EPZ004777 [21], and DS-437 [22], the first two of which
have been approved for clinical use. Currently, no inhibi-
tors are known for RNA MTases other than the universal
nucleoside analogue sinefungin and the natural cofactor
product S-adenosyl-homocysteine (SAH).
Based on extensive structural comparison with other
MTase families, and emerging evidence for links to
human diseases, RNA MTases are increasingly considered
promising drug targets [23]. Given the similarities in SAM
cofactor binding pockets across MTase families, it was
suggested to design drugs that simultaneously exploit the
cofactor and substrate binding pockets [23]. Recently,
a series of bisubstrate analogue encompassing an analogue
of the cofactor SAM covalently linked to the N6-position
of an adenosine, were synthesized [24]. These molecules
aim to mimic the substrate:cofactor bound state in which
a methyl group is transferred from SAM to the adenosine
N6-atom of substrate RNA during catalysis by m6A RNA
MTases.
As a proof-of-concept, we use the m6A RNA MTase RlmJ as
a model to test the binding mode of this series of bisubstrate
analogues to assess their use as inhibitors against m6A RNA
MTases, and their similarity in binding mode to the substrate:
cofactor binding during methyl transfer. We further tested the
broader capability of these bisubstrate analogues to bind to
an m1A RNA MTase protein (TrmK) related to RlmJ in
structure.
Results
The bisubstrate analogues increase the Tm of RlmJ
The bisubstrate analogues mimic the state at which the
N6-atom of the substrate adenosine in RNA performs nucleo-
philic attack on the ε C-atom of the transferred methyl group
in the natural cofactor SAM (Figure 1A). The synthesis of the
bisubstrate analogues [24] entailed joining a cofactor analogue
(CA) of SAM (Figure 1B) to the N6-atom of adenosine
through a variety of linkers, yielding six molecules; bisubstrate
analogue (BA) 1 to 6 (Figure 1C) [24]. To ensure diversity in
the chemical space, the linker was synthesized as either a short
chain of two C-atoms (Figure 1C, BA1 and −2), a longer chain
of three C-atoms (Figure 1C, BA3 and −4), or a urea unit
(Figure 1C, BA5 and −6). The bisubstrate analogues were
further synthesized with (BA2, −4, −6) or without
(BA1, −3, −5) the methionine group present in SAM and
SAH. The binding of the CA and BA1-6, as well as the
cofactor substrate SAM, cofactor product SAH, and the
known inhibitor sinefungin (Figure 1D) to RlmJ, was evalu-
ated using differential scanning fluorimetry (DSF). This tech-
nique measures the protein melting temperature (Tm), and
a change in protein Tm in the presence of a bisubstrate
analogue, implies formation of a protein:compound complex
[25]. First, binding of the CA, SAM, SAH, and sinefungin
were tested. RlmJ displayed an increased Tm-value with all
four molecules, compared to apo protein (Figure 1E). The
four molecules vary only by the atom or chemical group at
the δ-position: NH-group in CA, S+-CH3 group in SAM,
BA2BA1
BA5 BA6
BA3
ca SAM (cofactor)Adenosine in RNA 
(substrate)
Linker
region
CA (cofactor analogue)b
SAH (cofactor product)
Sinefungin (inhibitor)
d
e
****
****
****
**** **** ****
***
*
ns ns
BA4
Figure 1. Structure of the bisubstrate analogues and binding to RlmJ. (A) The structure of the substrate adenosine in RNA (black) and natural cofactor SAM (blue).
The point of linkage in the bisubstrate analogues (BA) is indicated with a double arrow (red). (B) The structure of the cofactor analogue (CA) used as building block
for the BA compounds. (C) A schematic overview of the structures of the six synthesized bisubstrate analogues; BA1 to 6. (D) The structure of the natural cofactor
product SAH and universal RNA MTase inhibitor sinefungin. (E) The melting temperature (Tm) for E. coli RlmJ as apo protein (no ligand) or in the presence of CA,
SAM, SAH, sinefungin or one of six m6A RNA MTase bisubstrate analogues (BA1-6) from C, measured using differential scanning fluorimetry. P values are indicated as
follows: ns = P > 0.05, * = P ! 0.05, *** = P ! 0.001, and **** = P ! 0.0001, n = 3.
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S-atom in SAH, and C-NH2 in sinefungin. The gradual
increase in Tm for RlmJ with CA < SAM < SAH < sinefungin
indicates that the nature of the δ-atom is important for either
direct interaction with the protein or for the ligand to adapt
a suitable conformation. Next, the six bisubstrate analogues
were tested for binding. These experiments yielded the largest
Tm shifts for RlmJ in the presence of the two compounds BA2
and BA4 (Figure 1E), indicating that these ligands form
a larger number of stabilizing protein interactions, compared
to BA1, −3, −5 and −6. A general Tm comparison of all
compounds showed that the methionine part likely is involved
in protein binding (BA1, −3, −5 compared to BA2, −4, −6)
and that an aliphatic linker is preferred (BA2, −4 compared to
BA6) for optimal protein interaction with RlmJ.
BA2 and BA4 are starting scaffolds for adenine-modifying
MTase inhibitors
In recent years, MTases have received considerable attention
as drug targets due to their link to human disease. The
bisubstrate analogues, BA2 and BA4, yielded the largest
shift in Tm for RlmJ. To test the relevance of these analogues
as inhibitors for RlmJ, KD-values were measured using iso-
thermal titration calorimetry (ITC) for RlmJ in the presence
of the SAM, sinefungin, BA2 or BA4. Sinefungin binds RlmJ
with a KD-value of 1.7 ± 0.2 μM (Figure 2A) and SAH with
a KD of 7.5 ± 0.9 μM (Figure 2B), highlighting the inhibitor
potential of sinefungin. The ITC data revealed that the ana-
logues, BA2 and BA4, bind RlmJ with low micro-molar
affinity with KD-values of 25 ± 3 μM and 30 ± 4 μM,
respectively (Figure 2C,D).
To test the specificity of the bisubstrate analogues
against m6A RNA MTases, their binding to another ade-
nine-modifying RNA MTase family was examined. The N1-
monomethylation of adenine (m1A) has been extensively
studied (reviewed in [26]), and thus we chose the m1A RNA
MTase, TrmK, from Mycoplasma capricolum, that catalyzes
formation of m1A in position 22 in tRNAs [27]. TrmK is
essential for many pathogenic bacteria [28,29], and there-
fore serves as an appropriate target for inhibitor develop-
ment. All six bisubstrate analogues, as well as CA, SAM,
SAH and sinefungin were tested against TrmK using DSF as
described. Tm-values were increased in the presence of the
CA, SAM, SAH, and sinefungin (Figure 2E). In contrast to
the result for RlmJ, the CA here resulted in a higher ΔTm
than SAM, suggesting that the N-atom in this molecule
could be directly bound to residues from TrmK but not
from RlmJ. Alternatively, binding of the CA could induce
stabilizing conformational changes in TrmK, not occurring
in RlmJ. For the bisubstrate analogues, BA2, BA4 and BA6,
resulted in the largest Tm increase for TrmK (Figure 2E).
The binding of BA2 and BA4 increased the Tm for both
RlmJ and TrmK, suggesting that these analogues would not
be inhibitory specific for m6A RNA MTases, but could
instead be used as starting scaffolds for synthesis for
both m1A and m6A RNA MTase inhibitors.
Structure determination of RlmJ and Trmk bound to SAH,
BA2, or BA4
To understand the Tm and KD differences between bisubstrate
analogues, the molecular binding mode of BA2 -or BA4 to
protein was investigated. Crystallisation assays were performed
with RlmJ or TrmK and each of these analogues. Experiments
were also performed for each protein with SAH for later direct
comparison with the cofactor part of BA2 and BA4. Crystals
were obtained for RlmJ bound to SAH, BA2, or BA4. TrmK
crystallised only in the presence of SAH. Structures were solved
for RlmJ:SAH to 1.61 Å, RlmJ:BA2 to 1.39 Å, RlmJ:BA4 to
2.10 Å, and TrmK:SAH to 2.36 Å (Table 1), each with one ligand
bound per active site. In RlmJ:BA4, the ligand adopted two
conformations, where one occupied chain A and C, and one
occupied chain B. The ligand in ChainD presented poor electron
density and could only be partly fitted. The multiple binding
modes for BA4 compared to the single mode for BA2 could
explain the lower KD-value determined for BA4, compared to
BA2. Interaction surface analysis [30] of the structures sug-
gested, that both RlmJ and TrmK were monomers in solution,
confirmed by size exclusion chromatography yielding
a monomeric molecular weight (MW) for both proteins
(Supplementary Figure 1A). The crystallised RlmJ structures
display a class I MTase Rossmann-fold and a helical subdomain
inserted at residues 47–98 (Figure 3A), similar to what was
previously described [6]. The structure of TrmK:SAH displayed
a class-I MTase Rossmann-fold core with an additional
C-terminal extension (residues 179–245) (Figure 3B) compar-
able to TrmK from Bacillus subtilis (PDB: 6Q56). The core class-
I Rossmann-fold of TrmK and RlmJ align with an RMSD of 2.9
Å2 over 160 Cα. Such a similarity agrees with the DSF data
suggesting that BA2 and BA4 could bind both proteins, and
consistently, an alignment of TrmK:SAH with both RlmJ:BA2
and -BA4 shows that both ligands can be spatially accommo-
dated in the active site of TrmK (Supplementary Figure S1B).
The bisubstrate analogues bind in two conformations
and near catalytic residues
In the RlmJ:BA4 structure, two distinctively different molecular
conformations are observed for the BA4 molecule: a folded
conformation, hereon named BA4(a) (Figure 4A,C), and an
extended conformation, hereon named BA4(b) (Figure 4B,C).
Each conformation was compared to the binding mode of SAH
in RlmJ:SAH to analyze their applicability to mimic the sub-
strate:cofactor binding state during methyl transfer. In RlmJ:
SAH, the ligand binds in a pocket lined with hydrophobic
residues and forms hydrogen bonds to residues H19, H42
and S100 via its methionine part, and E118, D143 and G144
via its adenosine part (Supplementary Figure S2A). Compared
to SAH, most parts of BA4(a) binds out of the usual cofactor
binding pocket (Figure 4A). π-π stacking of the two adenine
moieties induces a folded conformation of the compound that
displaces the central δ N-atom 1.7 Å from the expected posi-
tion. The substrate part and the cofactor adenine of BA4(a)
binds in between the cofactor and the expected substrate
800 S. OERUM ET AL.
binding pocket, and as a result, BA4(a) shares only its interac-
tion between the methionine part and residues H19 and H42
with SAH (Supplementary Figure S2C). A similar folded con-
formation was also assumed by BA2 in RlmJ:BA2 that, how-
ever, additionally shares the interaction with S100 with SAH
(Supplementary Figure S2B,S3A,B). Contrary to BA4(a), BA4
(b) occupies both the presumed substrate binding pockets and
parts of the cofactor binding pocket. In fact, relative to
a possible real substrate:cofactor binding mode with RNA and
SAM, BA4(b) deviates only by the orientation of the adenosine
in the cofactor part, which is rotated 120° out of the canonical
binding pocket for SAH due to a shift in R/S-configuration
around the central δ-atom (Figure 4B). The substrate part of
BA4(b) binds in the presumed substrate binding pocket, lined
with hydrophobic and aromatic residues, and forms hydrogen
bonds with residues N12, K18, and D164 (Supplementary
Figure S2D). Two of these residues were shown to be catalyti-
cally important: the strictly conserved K18 residue, and the
D164 residue from a conserved D/N-P-P-Y/F/W motif
[6,15,31]. D164 forms a hydrogen bond of 3.0 Å to the N6-
(c)
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Figure 2. Binding of bisubstrate analogues to RlmJ and TrmK. ITC curves for RlmJ with (A) SAH, (B) sinefungin, (C) BA2, and (D) BA4. Dissociation constant (KD) -and
stoichiometry (N) values are reported as mean ± standard deviation (SD). (E) The melting temperature (Tm) of TrmK as apo (no ligand) or in the presence of CA, SAM,
SAH, sinefungin or one of six m6A RNA MTase bisubstrate analogues (BA1-6), measured using differential scanning fluorimetry. P values are indicated as follows: * = P
! 0.05, *** = P ! 0.001, and **** = P ! 0.0001, n = 3.
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atom of the substrate base, and of 2.8 Å to the cofactor part of
BA4(b) (Figure 4D). It is stabilized by a hydrogen bond to K18
(2.7 Å), that further binds to the N1-atom (3.2 Å) of the
substrate base (Figure 4D). In this position, D164 could act as
the suggested proton acceptor during catalysis by increasing the
electron density of the N6-atom [6,15], and K18 is positioned
such that it fixates D164 for catalysis. The N6-atom is posi-
tioned 2.5 Å away from the ε C-atom (Figure 4B). Such a dis-
tance, in two non-linked moieties, would allow for an SN2
methyl transfer to the N6-atom after its deprotonation [31].
Y4 and H6 from the N-terminal region of RlmJ were also
shown to be important for activity, and suggested to contribute
to substrate binding [6]. The first 19 residues at the N-terminal
are highly flexible and rotate up to 88º between the apo open
conformation and the SAH-bound closed conformation [6].
A closed conformation of the N-terminal would sterically clash
with parts of the BA molecules, and thus these ligand-bound
structures assume the open conformation. For BA4(b), these
clashes are solely with the rotated adenosine from the cofactor
part, and thus the substrate base alone can be fitted nicely into
the closed conformation of RlmJ:SAH (Figure 4E). In this fit, the
two residues Y4 and H6 point towards the substrate base. The
side-chain O-atom of Y4 was shown to be more important for
activity than the aromatic ring [6]. In agreement with this, no π-
π stacking occurs between Y4 and the substrate base. Instead,
this O-atom is part of an intricate network of hydrogen bonds
that ultimately binds to the base via the catalytically important
K18 (Y4-H6-D15-L18-base) (Figure 4E). The close proximity of
the substrate base from BA4(b) to the catalytically important
residues (D164 and K18) of RlmJ, implies, that the extended
conformation of BA4(b) resembles the real m6A RNA MTase
substrate:cofactor bound state.
Ba4(b) is applicable for studying RNA recognition in
all m6a RNA and DNA MTases
Structural similarities of the active site across m6A RNA
MTase suggest that the substrate analogues, tested here for
RlmJ, could also be used to investigate RNA recognition of
other m6A RNA MTases. The crystal structure of
the m6A RNA MTase METTL16 has been solved in com-
plex with substrate RNA [13] without the cofactor, and the
Rossmann-fold of RlmJ aligns with this protein (PDB:
6DU4) with an RMSD of 2.9 Å2 over 287 Cα[32]. In the
METTL16:RNA structure, the substrate adenine binds in
a similar plane and position as the substrate adenine in BA4
(b) (Figure 5A). In METTL16, the adenine is swapped 180°
relative to the BA4(b) base, but the N6-atom to be methy-
lated are located only 1.5 Å apart. Compared to the 4.0 Å
distance between the N6-atom and δ N-atom in BA4(b), the
N6-atom in METTL16 is at a distance of 4.6 Å to the
corresponding S-atom of a modelled SAH molecule
(Figure 5A). Apart from similarities at the level of the
substrate base, the RNA from METTL16:RNA does not
model well onto RlmJ with multiple clashes observed with
the core Rossmann-fold. Taken together, a comparison of
BA4(b) with RNA-bound METTL16 indicates, that the sub-
strate part of BA4(b) could bind METTL16 in the position
of the RNA substrate, and might thus be used broadly to
study RNA binding in m6A MTases.
SAH
Rossmann-fold
C
Helical
subdomain
insert
N
(a)
SAH
C-terminal domain
Rossmann-fold
N
C
(b)
Figure 3. Crystal structures of RlmJ and TrmK. (A) RlmJ bound to SAH. The core Rossman-fold is shown in yellow. The helical subdomain insert is shown in orange.
SAH is shown in stick representation in yellow. (B) The crystal structure of TrmK bound to SAH. The core Rossman-fold is shown in light green. The C-terminal domain
is shown in dark green. The SAH ligand is shown in stick representation.
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In addition to resembling each other, the active site
of m6A RNA MTases also align well with active site compo-
nents of m6A DNA MTases. Thus, the bisubstrate analogues
might also be used to study substrate binding in this subfamily
of proteins. A DALI search comparing RlmJ pairwise with
the m6A DNA MTases T4Dam (PDB: 1YFL) or M.TaqI
(PDB: 1G38) yielded RMSD-values of 3.2 Å2 and 2.8 Å2 over
281 Cα, respectively [32]. T4Dam and M.TaqI were previously
crystallised in complex with substrate DNA, and one of the
cofactor analogues; sinefungin or 5′-[2-(amino)ethylthio]-5′-
deoxyadenosine (AETA), respectively. A superposition of
their cofactor analogues (sinefungin, AETA) with SAH and
BA4(b) in RlmJ reveals that the substrate adenine of BA4(b)
locates in the same area as the substrate base in M.TaqI (Figure
5B) and T4Dam (Figure 5C), resembling most that of T4Dam.
Interestingly, in these proteins the adenine base is bound in the
same plane as in BA4(b), emphasizing the potential of BA4 to
also mimic the substrate:cofactor bound state in DNA MTases,
further broadening the applicability of this molecule in DNA
binding studies.
Discussion
In this study, we successfully identify two bisubstrate analo-
gues that bind to the active site of RlmJ: BA2 or BA4. ITC
data for RlmJ with these compounds showed KD-values in the
low micromolar range. The values for BA2 and BA4 were
about 15-fold higher than that of sinefungin, but comparable
to KD-values found for the dual inhibitor DS-437 of 25 and 30
μM against the human protein MTases hPRMT5:hMEP50 and
hPRMT7, respectively [22]. Based on their corresponding IC50
-values of 5.9 ± 1.4 μM and 6.0 ± 0.5 μM, and the inactivity of
DS-437 towards 29 other human protein-, DNA- and RNA
MTases, this probe was deemed a promising template for the
development of potent and selective inhibitors for hPRMT5
and hPRMT7. We thus hypothesize that the BA2 and BA4
compounds could similarly serve as template scaffolds for
inhibitor design against m6A RNA MTases.
Binding investigation with BA2, BA4 and the m1A RNA
MTase protein TrmK revealed a similar pattern for this pro-
tein, compared to RlmJ. Thus, inhibitory optimization of
these compounds for m6A RNA MTases should aim to
increase not just affinity, but also specificity.
For optimization of affinity, some hints were provided from
the Tm of RlmJ in the presence of each substrate analogue.
Analogues which included the methionine part of the cofactor
displayed a larger increase in protein thermostability, compared
to analogues lacking this cofactor part. This indicates that the
methionine part of the analogues interacts directly with the
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Figure 4. Binding conformations adopted by BA4. (A) RlmJ protein bound to the folded conformation of BA4 (BA4(a)) (red). RlmJ:SAH is aligned with RlmJ:BA4 and
shown in yellow. The parts of BA4(b) involved in π-stacking are indicated, as well as the parts of the compound corresponding to the natural substrate -and cofactor.
The 1.7 Å displacement of the central δ N-atom from the expected position is indicated in as a dashed black line. (B) As for A, but presenting the extended
conformation of BA4 (BA4(b)) (blue). The point of rearrangement from S-configuration in SAH to R-configuration in BA4(b) is indicated, along with the resulting
degree of rotation (120°) for the cofactor part of BA4(b). The parts of the compound corresponding to the natural substrate -and cofactor are indicated. The distance
between the N6-atom of adenine and the ε C-atom from the cofactor part (dashed black line) is given in Å. (C) Fo-Fc of BA4(a) (top, red) and BA4(b) (bottom, blue)
contoured at 2.0 σ. The substrate – and cofactor parts are indicated for clarity. (D) RlmJ bound to BA4(b) (blue). Hydrogen bonds are indicated as dashed lines and
distances are shown in Å between both the N1-/N6-atoms of the BA4(b) substrate base, the cofactor part of BA4(b) that is bound similarly to SAH, and the
catalytically important residues; K18 and D164 (stick representation, purple). BA4(b) is shown in blue stick representation. (E) Superposition of RlmJ:BA4(b) (blue) with
RlmJ:SAH (yellow). The substrate base from BA4(b) is fitted into the closed conformation of RlmJ, which is adopted when the protein binds to SAH. Dashed lines
indicate the hydrogen bonds formed between different RlmJ residues (stick representation, yellow) in the closed conformation around the substrate base from BA4
(b). Distances are shown in Å.
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protein, as confirmed by our RlmJ:BA crystals structures.
A similar larger increase was also consistently observed for the
longer linker of three C-atoms (BA3,-4) compared to the linker
of two C-atoms (BA1,-2), or a urea unit (BA5,-6). Comparison of
the structure of BA2 containing a two C-atom linker (folded
conformation) with those of BA4 containing a three C-atom
linker (folded and extended conformation), indicates that
a longer linker is required to allow the molecule to adopt the
extended form. We thus suggest that future designs should
include the SAM methionine group and a linker of at least
three C-atoms length. A successfully optimized compound
would ultimately be used either as a small-molecule drug, or as
a cell-active chemical compound, to investigate the therapeutic
potential of targeting N6-monomethylation pathways. Such
a compound becomes even more interesting with the discovery
of the human m6A RNA MTase METTL16 and METTL3:
METTL14 complex, all related to RlmJ in structure, as these
targets have been associated with a number of cancers [18].
Structures of proteins in complex with RNA and cofactors
are difficult to obtain for a number of reasons: (1) the often-
low protein affinity for the modified base itself excludes the
use of just single nucleotides such as AMP or GMP for
structural studies, (2) RNA-binding often involves concomi-
tant binding of cofactors, complicating complex reconstitu-
tion, (3) the RNA has to be correctly folded and
homogeneous for facile crystallisation, and (4) incubation
in crystallisation trials requires completely RNase free con-
ditions. SAM-dependent MTases often co-crystallise easily
with the cofactor. Therefore, directly linking the substrate
base to this moiety at the point of nucleophilic attack to
mimic the substrate:cofactor bound state, facilitates struc-
tural studies by increasing RNA substrate base affinity, redu-
cing flexibility, and by-passing RNase contamination issues.
Using such linked molecules, we solved the co-crystal struc-
ture of RlmJ with either of two compounds: BA2 or BA4.
Structure analysis revealed that the adenine base in an
extended conformation of BA4 likely binds in the real sub-
strate binding pocket for substrate RNA. Thus, this molecule
might be used more generally as a tool to determine the
substrate binding site in other m6A RNA MTases.
Structural similarities between m6A RNA and DNA
MTases suggests that the here tested bisubstrate analogues
could also be used for m6A DNA MTases, further broad-
ening the applicability of these compounds.
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Figure 5. Comparison of RlmJ:BA4(b) with RNA-bound m6A RNA and DNA MTases. (A) Comparison of the position of the substrate base of BA4(b) (blue) from RlmJ:
BA4 and the corresponding base (A17) in the human homologue METTL16 co-crystallised with an RNA substrate (PDB: 6DU4) (orange). SAH (yellow) from RlmJ:SAH,
aligned with RlmJ:BA4, is shown for comparison. The methylated bases and all cofactors are shown in stick representation. (B) As for A, but compared to the
corresponding base (A606) from the DNA co-crystallised with m6A DNA MTase M.TaqI (PDB: 1G38) bound to the cofactor analogue 5′-[2-(amino)ethylthio]-5′-
deoxyadenosine (AETA) (orange). (C) As for A, but compared to the corresponding base (A608) from the DNA co-crystallised with m6A DNA MTase T4Dam (PDB: 1YFL)
bound to the cofactor analogue sinefungin (orange).
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The newly synthesized bisubstrate analogues [24] appear
with both the R- and S-configuration with respect to the δ
N-atom. The cofactor adenosine of the extended form of BA4
binds outside of the natural cofactor binding pocket due to an
R/S-configurational rearrangement. Using a BA containing
a carbon instead of the δ N-atom would allow to synthesize
BA with S-configuration and should favor the good position-
ing of the cofactor moiety into the catalytic site of the methyl-
transferase. A C-atom is already present in the only known
RNA MTase inhibitor; sinefungin, which displayed the high-
est Tm for RlmJ, of all tested compounds. The characteristics
of the atom at this position (the δ-atom) was shown through-
out our experiments to be generally important for protein
thermostability, and thus likely also for the KD.
Overall, we present here the first utilization of bisubstrate
analogues to study substrate recognition of m6A MTases. The
substrate parts of these molecules occupy the substrate bind-
ing pockets and might be used to study substrate binding and
mechanisms in protein throughout the m6A RNA and DNA
MTase families. Chemistry that allows coupling of the cofac-
tor to different positions in the RNA base or sugar, would
facilitate the production of a full co-crystallisation library of
MTase bisubstrate analogues, matching each family of pro-
teins catalyzing post-transcriptional modifications. Such
a library would strongly forward the fields understanding of
substrate recognition and enzymatic mechanisms of these
protein families.
Methods/materials
Cloning, expression and purification of RlmJ and TrmK
DNA fragments encoding the entire proteins of RlmJ (resi-
dues 1–280) or TrmK (residues 1–245) were subcloned into
the pET15b vector bearing an N-terminal His6-tag followed
by a thrombin protease cleavage site. Plasmids were trans-
formed into E. coli BL21(DE3) competent cells, cultured in
Lysogeny Broth at 37°C, and protein expression was induced
with 0.5 mM isopropyl β-D-1-thiogalactopyranoside for 3 h
growth at 37°C. Cell pellets from 1–2 L culture were lysed by
sonication, clarified by centrifugation, and the clarified lysate
was applied to immobilized metal affinity column (IMAC)
for purification. After IMAC, TrmK purity necessary for
crystallisation assays was reached (Supplementary Figure
S4) and TrmK was concentrated before storage at −80°C in
a buffer of 50 mM HEPES pH 7.5, 500 mM NaCl, 5%
glycerol, 1 mM dithiothreitol and 1 mM ethylenediami-
netetraacetic acid. Further purification of RlmJ was per-
formed by size exclusion chromatography (SEC) on
Superdex S75 PG (GE Healthcare). Parts of the expressed
protein was further treated with Thrombin protease for 4 h
at 22°C to remove the His6-tag and purified by SEC on
Superdex S75 PG (GE Healthcare). After these steps, RlmJ
purity necessary for crystallisation assays was reached
(Supplementary Figure S4). RlmJ was concentrated and
stored at −80°C in a buffer of 20 mM Tris pH 7.0, 150 mM
NaCl, 5% glycerol and 5 mM β-mercaptoethanol.
Analytical size exclusion chromatography (analytical SEC)
100 μL protein sample of 90 μM for RlmJ and 30 μM for
TrmK was injected onto a 24 mL Superdex Increase S75 10/
300 GL column (GE Healthcare). MW standards from Bio-
Rad containing thyroglobulin (670 kDa), γ-globulin (158
kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and vitamin
B12 (13.5 kDa) were used for calibration. MWs for RlmJ and
TrmK were determined from a linear plot of LOG [10](MW)
with the MW of each Bio-Rad standard proteins against their
elution volume.
Differential scanning fluorimetry (DSF)
DSF was performed in a 96-well plate using a CFX96Touch
real-time PCR detection system (Bio-Rad) with excitation and
emission filters of 450–490 and 515–530 nm, respectively.
Each well consisted of 2 µL protein in a buffer of 20 mM
HEPES pH 7.5, 150 mM NaCl to a final concentration of
5 µM, 2 µL of SYPRO ORANGE diluted 5000-fold in buffer
from the manufacturer’s stock (Invitrogen), and (if applicable)
2 µL ligand to 1 mM. Fluorescence intensities were measured
from 25 to 85°C with a ramp rate of 1°C/min. Tm was
determined by curve-fitting using GraphPad Prism v.5.01
software [25]. Data were evaluated using a standard P-test
according to standard procedure performed using the
GraphPad Prism v.5.01 software.
Isothermal titration calorimetry (ITC)
ITC measurements for the binding affinities between RlmJ
and SAH, sinefungin, BA2 or BA4 were performed at 25°C
using an ITC200 titration calorimeter (MicroCal/Malvern
Panalytical). The molecules were dissolved in protein buffer
of 20 mM Tris pH 7.0, 150 mM NaCl, 5% glycerol and 40 μL
of this was placed in a syringe. The molecules were titrated
into 200 μL of the protein in the cell. The first injection (0.2
μL) was followed by 23 injections for SAH and sinefungin and
19 injections for BA2 and BA4, each of 1.6 µL or 2 µL,
respectively. The heat of dilution for the molecules was mea-
sured for background subtraction. The titration curves were
analyzed using the Origin software (MicroCal) with a single
binding-site model, after exclusion of the first injection point.
Standard errors were estimated from the data spread and
from the uncertainty of the titrant concentration determina-
tion as previously described [33]. Dissociation constant
(KD) -and stoichiometry (N) values are reported as mean ±
standard deviation (SD).
Crystallisation, data collection, and structure
determination
Crystals of RlmJ (with BA2, BA4) or His6-RlmJ (with SAH)
were grown by vapor diffusion at 20°C, from sitting drops
composed of 200 nL of protein and 40 μL of reservoir solu-
tion. For His6-RlmJ bound to SAH, the protein concentration
was 13 mg/ml; pre-incubated with 760 µM SAH and crystals
grew with a reservoir solution containing 0.1M KSCN, 30%
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(w/v) polyethylene glycol methyl ether (PEG MME) 2000.
RlmJ bound to BA2 crystallised with a protein concentration
of 9 mg/ml, pre-incubated with 2.2 mM BA2 in a reservoir
solution containing 0.1M BIS-Tris pH 6.5, 25% (w/v)
PEG3350. RlmJ bound to BA4 crystallised with a protein
concentration of 9 mg/ml, pre-incubated with 2.7 mM BA4
in a reservoir solution of 0.1 M MMT pH 6.0, 25% (w/v)
PEG1500. For TrmK bound to SAH, crystals were grown by
vapor diffusion at 20°C, from sitting drops composed of 150
nL of protein and 40 μL of reservoir solution, with a protein
concentration of 1.1 mg/ml, pre-incubated with 2 mM SAH in
a reservoir solution of 0.2 M Li2SO4, 0.1 M HEPES pH 7.5,
25% (w/v) PEG3350. Crystals were cryoprotected with reser-
voir solution supplemented with 15% (v/v) glycol, and flash-
cooled in liquid nitrogen. Diffraction data were collected on
the Synchrotron Soleil beamline PX2 to 1.39 Å for RlmJ:BA2
and 2.10 Å for RlmJ:BA4, or at the European beamline ID23-2
to 1.61 Å for RlmJ:SAH and 2.36 Å for TrmK:SAH. Phases
were determined by molecular replacement in PHASER [34]
in the CCP4 Suite of programs [35], using an existing RlmJ
structure as search model (PDB: 4BLV) for RlmJ complexes,
and TrmK from Bacillus subtilis (PDB: 6Q56) for TrmK.
Modelling and refinement were carried out using Refmac
[36], COOT [37] and Phenix [38]. Density was visible for all
residues aside from the tag and loopy parts covering residues
52–58 and 231–233 in chain A of RlmJ:SAH, residues 52–58
in chain B of RlmJ:SAH, residues 52–56 in RlmJ:BA2, and
residues 1–2 and 53–57 in all chains of RlmJ:BA4.
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